The SYNAPSE-PD Parkinson's Study
Exploring the Study
The purpose of this study is to investigate whether our investigational medication, MN-302, can reduce motor symptoms and improve quality of life in individuals diagnosed with Parkinson’s disease. MN-302, a noncompetitive, low-trapping NMDA antagonist, targets overactive glutamate receptors implicated in the progression of Parkinson’s. Participants meeting study criteria will be randomly assigned to receive MN-302 or a placebo. This study aims to evaluate the medication’s potential to restore neurotransmitter balance and alleviate symptoms associated with Parkinson’s disease.
Our Mission
We harness cutting-edge brain science and advanced technologies to develop and test innovative therapies urgently needed for neurological disorders. Driven by compassion, creativity, and optimism, we are dedicated to finding new solutions to complex challenges, aiming to enhance the lives of those affected by these conditions.
About the Study Medication
MN-302 is a novel noncompetitive, low-trapping NMDA antagonist being developed by Mentara Bio. Based on the well-established safety and tolerability profile of similar compounds, MN-302 is formulated for once-daily oral administration. This innovative medication aims to modulate glutamate receptors implicated in Parkinson’s disease, offering a promising therapeutic approach to alleviate motor symptoms and enhance quality of life for patients.
Parkinson's Disease and Treatment
Currently, there are no approved medications that specifically address the root causes of Parkinson’s disease. However, research indicates that dysfunction of glutamate receptors plays a role in its progression. MN-302, a noncompetitive, low-trapping NMDA antagonist, is designed to rebalance glutamate levels without introducing significant new side effects. This innovative approach offers potential benefits for alleviating symptoms and enhancing quality of life in Parkinson’s patients.
Locating a research site in your area
Official study title: ‘A clinical trial of MN-302, a novel NMDA antagonist, to alleviate motor symptoms in participants with Parkinson’s disease’
For more details about the study and how to participate, please contact your healthcare provider or specialist. They can offer information on participation and guide you to relevant resources. If there are no current study locations in your area, please check back periodically for updates.
US SITES OPEN FOR EVALUATING PARTICIPANTS IN THE ELEVATE AUTISM STUDY:
Harvard Univeristy
Maritza28@hotmail.com
Boston, MA
+1 119 079 307
https://www.cnn.com
Columbia University
Arch12@yahoo.com
New York, NY
+1 149 166 389
https://dropbox.com
Boston College
Gabe_Jast@hotmail.com
Boston, MA
+1 157 634 429
https://pinterest.com
University of Texas
Elaina59@hotmail.com
Houston, TX
+1 119 760 686
https://www.apple.com/
UCLA
Jasen_Nicolas5@hotmail.com
Los Angeles, CA
+1 148 747 980
https://www.craigslist.org
About Us
Science
Glutamate, a primary neurotransmitter contributing to over 80% of brain activity, is pivotal in the management of symptoms and overall health improvement in individuals facing serious neuropsychiatric conditions like Parkinson’s disease.
Noncompetitive low-trapping NMDA antagonists
Mentara Bio is advancing noncompetitive, low-trapping NMDA antagonists engineered to target hyperactive glutamate receptors on neurons. Integrating this clinically-validated strategy with state-of-the-art imaging technology aims to identify individuals with Parkinson’s disease who may derive the greatest benefit from our therapies.
